Articles  |   January 2013
SEE Question
Article Information
Coagulation and Transfusion / Renal and Urinary Systems / Electrolyte Balance / Articles
Articles   |   January 2013
SEE Question
ASA Monitor 01 2013, Vol.77, 32.
ASA Monitor 01 2013, Vol.77, 32.
Administration of tranexamic acid to patients undergoing radical prostatectomy will MOST likely result in which of the following?
Tranexamic acid is a lysine analog known to decrease fibrinolysis, thus sustaining clots and reducing blood loss. Tranexamic acid is inexpensive and readily available worldwide. Unlike aprotinin, tranexamic acid has not been associated with renal failure or increased mortality. The Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial, published in 2009, demonstrated decreased mortality when tranexamic acid was given to hemorrhaging trauma patients in the first 3 hours after injury. CRASH-2 has prompted renewed interest in using tranexamic acid to reduce bleeding and transfusion requirements in other high-risk patients.
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Affiliation & Institution
I have a potential conflict of interest
Comment Title

This feature is available to Subscribers Only
ASA Member Login or Create an Account ×